ClinConnect announced a partnership with Conduit Pharmaceuticals Inc. to conduct a cocrystal development program to evaluate Conduit's AZD1656 compound. AZD1656 is a molecule with potential treatment applications currently in a wide variety of autoimmune disorders. The cocrystal program will seek to identify, characterize, and validate suitable cocrystal partners for AZD1656 to solve for current challenges associated with solubility, stability, and bioavailability.

Pharmaceutical cocrystals may improve vital physicochemical characteristics of a drug, including solubility, dissolution, bioavailability, and stability of pharmaceutical compounds, while maintaining its therapeutic activity. ClinConnect was founded with a philosophy to ensure patients have better access to the care they deserve. Starting with a platform that provides a flourishing community for patients and their healthcare teams, ClinConnect offers an easy-to-navigate, real-time map of every trial known to the FDA that proactively matches patients to relevant studies.

The company also works directly with industry through its innovative and patient-centric trial design, regulatory navigation, and connection with all stakeholders across the healthcare continuum to drive faster drug development and medical innovation, ultimately working through all possible avenues to connect patients with treatments that could save lives.